APO-MYCOPHENOLIC ACID 360 MG
MYCOPHENOLIC ACID (MYCOPHENOLATE SODIUM) : 360 MG · DIN 02372746 · APOTEX INC
Health Canada status: MARKETED
What is APO-MYCOPHENOLIC ACID?
APO-MYCOPHENOLIC ACID 360 MG contains MYCOPHENOLIC ACID (MYCOPHENOLATE SODIUM) : 360 MG. It is listed in the Health Canada Drug Product Database under DIN 02372746, held by APOTEX INC, supplied as TABLET (ENTERIC-COATED) for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Jul-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02372746 |
|---|---|
| Brand name | APO-MYCOPHENOLIC ACID |
| Generic / active ingredient | MYCOPHENOLIC ACID (MYCOPHENOLATE SODIUM) : 360 MG |
| Manufacturer | APOTEX INC |
| Strength | 360 MG |
| Dosage form | TABLET (ENTERIC-COATED) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AA06 MYCOPHENOLIC ACID |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Jul-2014 |
What can be used instead?
Other Canadian products sharing ATC code L04AA06 MYCOPHENOLIC ACID. 24 of 41 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-MYCOPHENOLATE | 250 MG | CAPSULE | ACCORD HEALTHCARE INC | MARKETED | DIN 02383780 |
| ACH-MYCOPHENOLATE | 500 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02378574 |
| APO-MYCOPHENOLIC ACID | 180 MG | TABLET (ENTERIC-COATED) | APOTEX INC | MARKETED | DIN 02372738 |
| CELLCEPT | 200 MG | POWDER FOR SUSPENSION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02242145 |
| CELLCEPT | 250 MG | CAPSULE | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02192748 |
| CELLCEPT | 500 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02237484 |
| CELLCEPT I.V. | 500 MG | POWDER FOR SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02240347 |
| JAMP MYCOPHENOLIC ACID | 180 MG | TABLET (ENTERIC-COATED) | JAMP PHARMA CORPORATION | MARKETED | DIN 02518538 |
| JAMP MYCOPHENOLIC ACID | 360 MG | TABLET (ENTERIC-COATED) | JAMP PHARMA CORPORATION | MARKETED | DIN 02518511 |
| JAMP-MYCOPHENOLATE | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02380382 |
Who else supplies MYCOPHENOLIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MYCOPHENOLIC ACID appears in 252 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.